Creative Medical up on U.S. FDA nod for diabetes therapy

Creative Medical Technology Holdings

03/11/2022 13:02

** Shares of biotech Creative Medical Technology Holdings 
Inc  CELZ.O  up 19.6% at 48 cents before the bell
    ** Co says U.S. FDA has cleared its Investigational New Drug
(IND) application enabling to proceed with initiating a clinical
trial for diabetes therapy AlloStem 
    ** CELZ says primary objective of the study is to evaluate
AlloStem in patients with newly diagnosed Type 1 diabetes 
    ** Co expects patient recruitment to begin in Q1 2023 
    ** CELZ down 81.9% YTD, as of Wednesday's close
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))